Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
William Msemburi et al.
Summary: The World Health Organization has been tracking the progression of the COVID-19 pandemic since the beginning of 2020. Reported statistics on COVID-19 mortality vary across countries due to testing access, diagnostic capacity, and inconsistent cause of death certification. This study provides a comprehensive measurement of the pandemic's impact by estimating excess deaths globally, which are 2.74 times more than reported COVID-19 deaths. There are significant variations in excess death estimates across different regions, highlighting the need for better reporting.
Article
Clinical Neurology
Edouard Januel et al.
Summary: Recent studies suggest a lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination in patients treated with anti-CD20 and fingolimod. This study evaluated cases of COVID-19 occurring after vaccination among patients with MS and NMO, finding mild severity in cases reported. The results emphasize the need for a third COVID-19 vaccine dose for anti-CD20 treated patients and call for further prospective studies on vaccine efficacy in MS and NMO patients.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Maria Pia Sormani et al.
Summary: This study compares the outcomes of COVID-19 in patients with multiple sclerosis (MS) in Italy with the expected outcomes in the general population. The risk of severe events, including hospitalization, ICU admission, and death, was found to be twice as high in the MS cohort compared to the age- and sex-matched Italian population. The increased risk was primarily associated with disease severity and comorbidities, but there was also a higher risk of hospitalization in patients on anti-CD20 therapies and a lower risk in patients on interferon.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2022)
Article
Clinical Neurology
Tim Spelman et al.
Summary: The study aimed to analyze the association between MS disease-modifying therapy (DMT) exposure and hospitalization in patients with COVID-19. Among the 476 reported COVID-19 cases in MS patients in the Swedish MS registry, 61.3% were confirmed cases. Of these confirmed infections, 23.2% required hospitalization, with a higher hospitalization rate observed in patients on rituximab compared to other DMTs.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Medicine, General & Internal
Tommy Nyberg et al.
Summary: The Omicron variant shows lower severity compared to Delta, especially in terms of hospital admission and death, with significant variations by age. Unvaccinated cases experience a larger reduction in intrinsic severity, while vaccinated cases experience reduced vaccine effectiveness. Booster vaccination with mRNA vaccines provides over 70% protection against hospitalization and death in breakthrough Omicron infections.
Article
Medicine, General & Internal
Andreas Tolf et al.
Summary: For an optimal vaccine response from tozinameran, rituximab-treated patients with multiple sclerosis should be vaccinated as soon as possible, with rituximab treatment delayed until B-cell counts have reached at least 40/mu L. An additional vaccination with tozinameran should be considered at that point.
Article
Clinical Neurology
Irene Schiavetti et al.
Summary: Patients with multiple sclerosis treated with ocrelizumab and fingolimod have a higher risk of breakthrough SARS-CoV-2 infections, while the rate of severe infections is significantly lower in all disease-modifying therapy groups excluding ocrelizumab.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Huah Shin Ng et al.
Summary: This study examined the association between disease-modifying drugs (DMDs) for multiple sclerosis (MS) and survival, and found that exposure to DMDs is associated with a lower hazard of mortality. Early initiation of DMDs is associated with a significant survival advantage, although this advantage diminishes over time.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2022)
Article
Clinical Neurology
Johannes Sverre Willumsen et al.
Summary: Excess mortality among persons with multiple sclerosis (pwMS) has declined during the past seven decades, possibly due to improved diagnostics, better symptomatic treatment, and access to disease-modifying treatments (DMTs).
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Immunology
Judith S. Brand et al.
Summary: This study explored the associations between disease course and disability status in multiple sclerosis (MS) patients and the risk of serious infections. The results showed that progressive disease and higher disability scores were associated with a greater risk of serious infections, while relapsing-remitting disease and lower disability scores were associated with a lower risk. These findings suggest that disease course and disability status should be considered in the management and monitoring of MS patients.
BRAIN, BEHAVIOR, & IMMUNITY - HEALTH
(2022)
Article
Clinical Neurology
Steve Simpson-Yap et al.
Summary: Using data from 12 sources in 28 countries, this study examined the characteristics of COVID-19 severity in people with MS, particularly those taking immunosuppressive therapies. The results showed that older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Additionally, rituximab was consistently associated with increased risk of hospitalization, ICU admission, and need for ventilation, while ocrelizumab was mainly associated with hospitalization and ICU admission.
Article
Clinical Neurology
Amber Salter et al.
Summary: This study examined outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with multiple sclerosis. The study found that ambulatory disability, older age, male sex, Black race, cardiovascular comorbidities, and recent corticosteroid use were associated with increased odds of worse clinical severity in MS patients with COVID-19. Knowledge of these risk factors may help improve the treatment and monitoring of these patients.
Article
Clinical Neurology
Livnat Brill et al.
Summary: Patients with MS treated with ocrelizumab showed comparable SARS-CoV-2-specific T-cell responses with healthy controls but lower antibody response following vaccination. This study provides reassurance regarding the potential role of T cells in protection from severe disease and will aid in the development of consensus guidelines for MS treatment during the COVID-19 pandemic.
Article
Clinical Neurology
Anat Achiron et al.
Summary: The study found that after receiving the COVID-19 vaccine, MS patients who were either untreated or treated with cladribine showed a high level of protective humoral immunity, similar to healthy subjects. However, only a small percentage of MS patients treated with ocrelizumab and fingolimod developed a humoral immune response.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Article
Clinical Neurology
Katharine Harding et al.
Article
Medicine, General & Internal
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Clinical Neurology
Celine Louapre et al.
Article
Neurosciences
EUROPEAN JOURNAL OF NEUROLOGY
(2018)
Article
Neurosciences
EUROPEAN JOURNAL OF NEUROLOGY
(2017)
Article
Medicine, General & Internal
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2017)
Article
Medicine, General & Internal
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2017)
Review
Medicine, General & Internal
Irene Tramacere et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2015)
